medRxiv preprint doi: https://doi.org/10.1101/2021.07.05.21260050; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada, from December to July, 2021

David N. Fisman MD MPH and Ashleigh R. Tuite PhD MPH

Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

Address reprint requests and correspondence to:

David Fisman, MD MPH FRCP(C)

Room 686, 155 College Street, Toronto, Ontario, M5T 3M7

Email: david.fisman@utoronto.ca

The research was supported by a grant to DNF from the Canadians Institutes for Health Research (2019 COVID-19 rapid researching funding OV4-170360).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.07.05.21260050; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

The period from February to June 2021 was one during which initial wild-type SARS-CoV-2 strains were supplanted in Ontario, Canada, first by variants of concern (VOC) with the N501Y mutation (principally alpha, beta and gamma variants), and then by the delta variant. We demonstrate that these emerging VOCs were associated with an increase in virulence, as measured by risk of hospitalization, intensive care unit admission, and death. Compared to non-VOC SARS-CoV-2 strains, and adjusting for comorbidity, age and sex of cases, and temporal trends, the elevation in risk associated with N501Y-positive variants was 74% (62-86%) for hospitalization; 138% (105-176%) for ICU admission; and 83% (57-114%) for death. Increases with delta variant were even larger: 105% (80-133%) for hospitalization; 241% (163-344%) for ICU admission; and 121% (57-211%) for death. The progressive increase in transmissibility and virulence of SARS-CoV-2 variants will result in a significantly larger, and more deadly, pandemic.

medRxiv preprint doi: https://doi.org/10.1101/2021.07.05.21260050; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

Novel SARS-CoV-2 variants of concern (VOC), including viral strains carrying the N501Y and/or E484K mutations, were first identified in Ontario, Canada in December 2020 [1]. While infection with such strains was initially uncommon, these variants outcompeted earlier SARS-CoV-2 lineages in Ontario, and as of late April 2021 comprised almost all new infections in Ontario[1]. In April 2021, the B.1.617.2 variant, now known as the "delta" variant under revised World Health Organization nomenclature, emerged in the province and outcompeted earlier VOCs, representing the majority of infections as of July 2021 [2, 3].

This serial replacement by emerging variants reflects progressively higher effective reproduction numbers which allow novel variants to outcompete previously dominant strains in the face of identical disease control interventions [4]. However, VOCs are also concerning because of an apparent increase in virulence, with increased risk of hospitalization, intensive care unit admission and death, after adjustment for age and other predictive factors [5-8]. Although the increased virulence of strains with the N501Y mutation relative to strains which lack this mutation has been described [5-7], only limited information is available on the virulence of infection with the delta variant, relative to earlier N501Y-positive variants (e.g., alpha, beta, and gamma variants) [8]. We sought to use Ontario's COVID-19 case data to evaluate the virulence of N501Y-positive variants relative to earlier SARS-CoV-2 strains, and also to evaluate the virulence of the delta variant of SARS-CoV-2 relative to N501Y-positive variants of concern.

medRxiv preprint doi: https://doi.org/10.1101/2021.07.05.21260050; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Methods

Data Sources

We created a retrospective cohort of people in Ontario testing positive for SARS-CoV-2 and screened for variants of concern, with dates of case report between February 3 and July 1, 2021. Case information was extracted from the Ontario provincial Case and Contact Management (CCM) database as described elsewhere [9]. Although VOC cases were identified in Ontario beginning in December 2020, systematic screening was not implemented until February 3, 2021, after which time all COVID-19 PCR positive specimens with a cycle threshold (Ct) value ≤ 35 were screened for the N501Y mutation using a single nucleotide polymorphism real-time PCR assay developed at the Public Health Ontario Laboratory. On March 22, 2021, Ontario initiated universal screening for N501Y and E484K mutations using a multiplex real-time PCR assay on all specimens testing positive for SARS-CoV-2 with a Ct value ≤35. Whole genome sequencing (WGS) was performed on a 5% sample of specimens regardless of the presence of mutations. Initially all specimens with the N501Y and/or E484K mutation and Ct value ≤ 30 were sequenced; however, as of June 2021 routine WGS was no longer performed on specimens without E484K. By late April 2021, more than 90% of infections in Ontario were screen positive for N501Y(Figure 1); subsequently, N501Y mutations became less common, and N501Y-negative specimens subjected to WGS were demonstrated to be predominantly delta variant, with delta representing > 60% of new infections in Ontario on July 1, 2021 [2, 3]. Analyses were restricted to individuals with infection episode dates from February 3, 2021 onwards, whose viral isolate had been screened for a VOC. Cases were classified as N501Y-positive (screening positive for N501Y or identified as alpha, beta, or gamma by WGS), probable delta variant (identified by WGS or negative for N501Y after May 1, 2021), or not VOC (all remaining

medRxiv preprint doi: https://doi.org/10.1101/2021.07.05.21260050; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

cases). Individuals for whom VOC screening information was not available (N = 33,694), or for whom screening could not be completed (N = 13,841) were excluded from the analysis. We further restricted our analysis to individuals without a record of long-term care residence, as the epidemiology and severity of SARS-CoV-2 infection in long-term care home residents have been distinct in Ontario [10, 11].

We constructed multivariable logistic regression models with hospitalization, intensive care admission, and death as dependent variables. Models adjusted for age (by 10-year increments), male sex, time (modeled as a week-on-week linear trend), documented major comorbidity (including documented asthma, COPD, hematological disease, liver disease, cardiac disease, diabetes, immune compromise, renal disease, neurological disease, or malignancy). Hospitalization and ICU models were also adjusted for pregnancy, which was excluded from models evaluating death due to the rarity of fatalities among pregnant individuals. Due to geographic variation in prevalence of variants, health units were included as indicator variables. In a separate analysis, we explored the apparent linear increase in virulence from non-VOC to N501Y-positive VOC to delta variant by modeling this progression as a 3-level ordinal variable.

medRxiv preprint doi: https://doi.org/10.1101/2021.07.05.21260050; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Results

We included 216,678 cases in our analysis, with episode dates between February 3 and June 27, 2021. Changes over time in incidence of infections by VOC status, and in incidence of infections resulting in ICU admission, are presented in **Figure 1**. Among all infections, 77% were infections with N501Y-positive VOC; 2.2% were classified as probable delta variant infections. In crude comparisons, there were significant differences between variants in probability of hospitalization and ICU; individuals with N501Y-positive variants and probable delta infection were significantly younger and less likely to have comorbidities than individuals with non-VOC infections; VOC infections were more common in the Greater Toronto and Hamilton area (GTHA, the province's largest metropolitan area) than in the province as a whole; delta variant infections were less common in Ottawa (the province's second largest metropolitan area) than in the province as a whole (**Table 1**).

After adjustment for age, sex, comorbidities, and temporal trend, large and significant increases in the risk of hospitalization, ICU admission, and death were seen with both N501Y-positive VOC, and probable delta variant infections, relative to non-VOC (**Table 2**). Increases were larger with delta variant infection than with N501Y-positive VOC, with a relative increase in risk of hospitalization, ICU admission and death of 54%, 91% and 65%, respectively (**Table 3**).

medRxiv preprint doi: https://doi.org/10.1101/2021.07.05.21260050; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Discussion

The emergence of novel SARS-CoV-2 variants of concern has slowed progress against the pandemic in three distinct ways: (i) by increasing transmissibility and the disease's reproduction number; (ii) by increasing immune escape and diminishing vaccine effectiveness; and (iii) by increasing the virulence of SARS-CoV-2 infection. Credible reports of enhanced virulence of VOC with the N501Y mutation have emerged over the past several months [5-7], but to our knowledge this is one of the first analyses to demonstrate enhanced virulence of the delta variant [8].

We show that in the Canadian province of Ontario, VOCs with the N501Y mutation were associated with a markedly increased risk of hospitalization, intensive care unit admission and death among infected individuals, but that the delta variant, which is now supplanting these other VOCs in Ontario, has increased these risks even further. Individuals infected with VOCs were, on average, younger and less likely to have comorbid conditions than those infected with non-VOC, but nonetheless had higher crude risks of hospitalization and ICU admission. Once we adjusted for confounding factors such as age, comorbidity, and temporal trends, elevated per-infection risk, including risk of death, remained markedly higher with VOCs, and with delta in particular. Indeed, given the relatively small number of delta infections in our time series, it is remarkable that a clear and significant elevation of risk of even uncommon, delayed outcomes, such as death, is readily visible in our analysis.

Canada is now one of the most widely vaccinated countries in the world with respect to SARS-CoV-2, and this vaccination has undoubtedly blunted the impact of emergence of these VOCs.

medRxiv preprint doi: https://doi.org/10.1101/2021.07.05.21260050; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

A key limitation of our dataset is that it lacks data on individual-level vaccination status. We are indirectly modeling the impact of vaccination for prevention of severe illness by incorporating a linear trend term in our model. We do likely see a countervailing effect of vaccination in our data with a week-on-week reduced risk of hospitalization, ICU admission and death of approximately 2%, 4% and 6%, respectively. Inasmuch as SARS-CoV-2 vaccines in use in Canada appear to diminish the severity of infection even when vaccine fails to prevent infection, the differences in virulence we report here are most likely to represent a lower bound. This diminution of apparent effect is likely exacerbated by our likely having misclassified early delta variant infections as non-VOC due to the absence of routine screening for characteristic delta mutations; in other words, our estimates of excess risk for delta are likely biased towards the null.

In summary, we demonstrate that in the Canadian province of Ontario, despite widespread vaccination and VOC infections occurring more frequently in younger and healthier individuals, VOCs are associated with a substantial increase in virulence, including increased risk of death. The emerging delta variant is more virulent than previously dominant N501Y-positive VOCs . Combined with increased transmissibility and immune escape, these VOCs represent a significant escalation in risk to public health during the SARS-CoV-2 pandemic.

Table 1. Characteristics of Study Cohort by Infecting Variant.

Descriptor	All	VOC "Not Detected"	N501Y+ VOC	Probable Delta Variant	P-value
Total Cases	216,678	44,939	166,838	4,901	
Hospitalized (%)	11,211 (5.17)	1,959 (4.36)	8,950 (5.36)	302 (6.16)	<0.001
Admitted to ICU	2,347 (1.08)	340 (0.76)	1,934 (1.12)	73 (1.49)	< 0.001
Died	1805 (0.83)	381 (0.85)	1,393 (0.83)	31 (0.63)	0.29
Male (%)	106,904 (50.66)	22,148 (50.72)	82,344 (50.64)	2,412 (50.79)	0.95
Under 60 years	186,066 (85.84)	37,839 (84.20)	143,869 (86.23)	4,298 (87.70)	< 0.001
Comorbidity*	10,710 (4.94)	3,010 (6.70)	7,508 (4.50)	192 (3.92)	< 0.001
Pregnancy	566 (0.26)	135 (0.30)	419 (0.25)	4901 (0.24)	0.19
Geography					
GTHA†	157,030 (72.47)	27,352 (60.86)	126,003 (75.52)	3,675 (74.98)	<0.001
Ottawa	9,234 (4.26)	1,968 (4.38)	7,234 (4.34)	32 (0.065)	<0.001

NOTE: P-values based on chi-squared test.

*Comorbidities include documented asthma, COPD, hematological disease, liver disease, cardiac disease, diabetes, immune compromise, renal disease, neurological disease, or malignancy.

†GTHA, Greater Toronto Area and Hamilton, large conurbation in Central Ontario consisting of 6 health units (Toronto, Peel, Durham, Halton, York and Hamilton).

Table 2. Multivariable Logistic Regression Models Predicting Outcomes According to Infecting Variant

	Hospitalization		ICU Admission		Death	
Covariate	**OR**	**95% CI**	**OR**	**95% CI**	**OR**	**95% CI**
Probable delta variant	2.05	(1.80 to 2.33)	3.41	(2.63 to 4.44)	2.21	(1.57 to 3.11)
N501Y+ variant	1.74	(1.62 to 1.86)	2.38	(2.05 to 2.76)	1.83	(1.57 to 2.14)
Male sex	1.3	(1.24 to 1.35)	1.58	(1.45 to 1.73)	1.66	(1.50 to 1.83)
Age (per 10-year increase)	1.92	(1.90 to 1.95)	1.77	(1.73 to 1.81)	2.78	(2.69 to 2.88)
Comorbidity	2.67	(2.50 to 2.84)	2.44	(2.17 to 2.74)	2.28	(2.01 to 2.60)
Pregnancy	6.27	(4.47 to 8.60)	6.46	(3.42 to 12.21)	---	---
Series week	0.985	(0.979 to 0.991)	0.962	(0.950 to 0.975)	0.934	(0.920 to 0.949)

Table 3. Relative Increase in Hospitalization, ICU Admission and Death with Delta Variant as Compared to N501Y-Positive VOC.

Outcome	Effect of Delta vs. N501Y+ VOC		
	OR	LCL	UCL
Hospitalization	1.54	1.46	1.63
ICU Admission	1.91	1.70	2.15
Death	1.65	1.44	1.89

Figure 1. Trends in SARS-CoV-2 Case Occurrence and ICU Admission by Variant, Ontario, Canada, February-June 2021. Cases of SARS-CoV-2 infection (left) and ICU admission (right) in Ontario, Canada by episode onset date (February 3 to June 27, 2021). Most infections during this period were with N501Y-positive variants of concern (VOC) (red); serial strain replacement occurred during this period with N501Y-positive VOCs supplanting non-VOC infections (blue), before increasingly being supplanted by probable delta VOC infections (green).



medRxiv preprint doi: https://doi.org/10.1101/2021.07.05.21260050; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References

1. Tuite AR, Fisman DN, Odutayo A, et al. COVID-19 hospitalizations, ICU admissions and deaths associated with the new variants of concern. Available via the Internet at https://doi.org/10.47326/ocsat.2021.02.18.1.0. Last accessed July 5, 2021. *Science Briefs of the Ontario COVID19 Science Advisory Table*. 2021;1(18)

2. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Epidemiologic summary: SARS-CoV-2 whole genome sequencing in Ontario, June 30, 2021. Available via the Internet at https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-sars-cov2-whole-genome-sequencing-epi-summary.pdf?sc_lang=en. Last accessed July 5, 2021. Toronto, Ontario: The Queen's Printer for Ontario; 2021.

3. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Epidemiologic summary: Estimating the prevalence and growth of SARS-CoV-2 variants in Ontario using mutation profiles. Available via the Internet at https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-prevalence-growth-voc-mutation-epi-summary.pdf?sc_lang=en Last accessed July 5, 2021. Toronto, Ontario: The Queen's Printer for Ontario; 2021.

4. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. Apr 9 2021;372(6538)doi:10.1126/science.abg3055

5. Nyberg T, Twohig KA, Harris RJ, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. *BMJ*. Jun 15 2021;373:n1412. doi:10.1136/bmj.n1412

medRxiv preprint doi: https://doi.org/10.1101/2021.07.05.21260050; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

6. Bager P, Wohlfahrt J, Fonager J, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. *Lancet Infect Dis*. Jun 22 2021;doi:10.1016/S1473-3099(21)00290-5

7. Funk T, Pharris A, Spiteri G, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. *Euro Surveill*. Apr 2021;26(16)doi:10.2807/1560-7917.ES.2021.26.16.2100348

8. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health S, the EIIC. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet*. Jun 26 2021;397(10293):2461-2462. doi:10.1016/S0140-6736(21)01358-1

9. Fisman DN, Greer AL, Hillmer M, O''Brien S, Drews SJ, Tuite AR. COVID-19 Case-Age Distribution: Correction for Differential Testing by Age

. medRxiv 2020091520193862; doi: https://doiorg/101101/2020091520193862 Available via the Internet at https://wwwmedrxivorg/content/101101/2020091520193862v1fullpdf Last accessed July 5, 2021. 2020;

10. Stall NM, Jones A, Brown KA, Rochon PA, Costa AP. For-profit long-term care homes and the risk of COVID-19 outbreaks and resident deaths. *CMAJ*. Aug 17 2020;192(33):E946-E955. doi:10.1503/cmaj.201197

11. Fisman DN, Bogoch I, Lapointe-Shaw L, McCready J, Tuite AR. Risk Factors Associated With Mortality Among Residents With Coronavirus Disease 2019 (COVID-19) in Long-term Care Facilities in Ontario, Canada. *JAMA Netw Open*. Jul 1 2020;3(7):e2015957. doi:10.1001/jamanetworkopen.2020.15957